Quantifying hypertension in patients with cancer treated with sorafenib

被引：9

作者：

Rini, Brian I. ^{[1
]}

机构：

[1] Cleveland Clin Taussig Canc Inst, Cleveland, OH USA

来源：

LANCET ONCOLOGY | 2008年 / 9卷 / 02期

关键词：

D O I：

10.1016/S1470-2045(08)70009-3

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：86 / 87

页数：2

共 5 条

[1]

AMATO RJ, 2007, P AM SOC ONCOL, V25

[2] Phase II placebo-controlled randomized discontinuation trial of sorafnib in patients with metastatic renal cell carcinoma [J].

Ratain, Mark J. ;

Eisen, Tim ;

Stadler, Walter M. ;

Flaherty, Keith T. ;

Kaye, Stan B. ;

Rosner, Gary L. ;

Gore, Martin ;

Desai, Apurva A. ;

Patnaik, Amita ;

Xiong, Henry Q. ;

Rowinsky, Lric ;

Abbruzzese, James L. ;

Xia, Chenghua ;

Simantov, Ronit ;

Schwartz, Brian ;

O'Dwyer, Peter J. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (16) :2505-2512

[3] Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study [J].

Rixe, Olivier ;

Bukowski, Ronald M. ;

Michaelson, M. Dror ;

Wilding, George ;

Hudes, Gaty R. ;

Bolte, Oliver ;

Motzer, Robert J. ;

Bycott, Paul ;

Liou, Katherine F. ;

Freddo, James ;

Trask, Peter C. ;

Kim, Sinil ;

Rini, Brian I. .

LANCET ONCOLOGY, 2007, 8 (11) :975-984

[4] Mechanisms of hypertension associated with BAY 43-9006 [J].

Veronese, ML ;

Mosenkis, A ;

Flaherty, KT ;

Gallagher, M ;

Stevenson, JP ;

Townsend, RR ;

O'Dwyer, PJ .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (09) :1363-1369

[5]

WU S, LANCET ONCOL, V9, P117

← 1 →